Leerink Swann Initiates Pacira Pharmaceuticals With Market Perform

Analysts at Leerink Swann initiated coverage on Pacira Pharmaceuticals Inc PCRX with a Market Perform rating. The target price for Pacira Pharmaceuticals is set to $86. Pacira Pharmaceuticals shares have dropped 11.28 percent over the past 52 weeks, while the S&P 500 index has surged 8.07 percent in the same period. Pacira Pharmaceuticals' shares rose 1.35 percent to close at $78.18 yesterday.